Skip to main content

Can you take Gevratonic with Sarecycline?

1 drug interaction and 3 additional warnings found for the following 2 drugs:

Add/remove drugs

Drug interactions

Moderate drug interactions

Moderate:

multivitamins with minerals sarecycline

Applies to: Gevratonic (multivitamin with minerals) and sarecycline

In general, multivitamins with minerals and sarecycline should not be taken orally at the same time. Products that contain aluminum, calcium, iron, magnesium, zinc and/or other minerals may interfere with the absorption of sarecycline into the bloodstream and reduce its effectiveness in treating your infection. If possible, it may be best to avoid taking multivitamins with minerals while you are being treated with sarecycline. Otherwise, you should separate their dosing times by as much as possible, usually at least 2 to 4 hours. Talk to your healthcare provider if you are unsure whether your medications contain something that could potentially interact or if you have questions on how to take this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Food/lifestyle interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Disease interactions

3 potential interactions Applies to: 3 conditions, including Liver Disease, Noninfectious Colitis, and Renal Dysfunction.

Liver Disease

Moderate:

sarecycline

Sarecycline has a moderate potential interaction with Liver Disease.

The effect of end-stage renal disease (ESRD) or severe hepatic impairment (Child-Pugh C) on sarecycline pharmacokinetics has not been assessed. Caution is advised if used in these patients.

Noninfectious Colitis

Major:

sarecycline

Sarecycline has a major potential interaction with Noninfectious Colitis.

Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis. The most common culprits include clindamycin and lincomycin. Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development. Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea after antibacterial use. Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary. Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity. Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.

Renal Dysfunction

Moderate:

sarecycline

Sarecycline has a moderate potential interaction with Renal Dysfunction.

The effect of end-stage renal disease (ESRD) or severe hepatic impairment (Child-Pugh C) on sarecycline pharmacokinetics has not been assessed. Caution is advised if used in these patients.

More resources

Gevratonic

A total of 112 drugs are known to interact with Gevratonic.

sarecycline

A total of 255 drugs are known to interact with sarecycline.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.